11C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas

Clinical Nuclear Medicine

Volumn 39, Issue 9, 2014, Pages 791-798

  D'Souza, Maria M ^a   Sharma, Rajnish ^a   Jaimini, Abhinav ^a   Panwar, Puja ^a   Saw, Sanjiv ^a   Kaur, Prabhjot ^a   Mondal, Anupam ^a   Mishra, Anil ^a   Tripathi, Rajendra P ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

brain tumors; MR perfusion; MR spectroscopy

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; METHIONINE C 11; N ACETYLASPARTIC ACID; TEMOZOLOMIDE; GADOLINIUM CHELATE; CARBON; METHIONINE; METHIONINE METHYL ESTER; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; ARTICLE; BRAIN BLOOD VOLUME; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CHOLINE TO CREATINE RATIO; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GLIOMA; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; RADIOLOGICAL PARAMETERS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR RECURRENCE; ANGIOGRAPHIC INJECTOR; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; NEUROSURGERY; PET-CT SCANNER; RECURRENT DISEASE; SCHOOL CHILD; YOUNG ADULT; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; EVALUATION STUDY; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CARBON RADIOISOTOPES; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84906058852     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000532     Document Type: Article

References (59)

1. Ullrich RT, Kracht L, Brunn A, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50:1962-1968.
2. Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. J Neuroradiol. 2010;37:89-97.
3. Lichy MP, Henze M, Plathow C, et al. Metabolic imaging to follow stereotactic radiation of gliomasVthe role of 1H MR spectroscopy in comparison to FDGPET and IMT-SPECT [in German]. Rofo. 2004;176:1114-1121. (Pubitemid 39118852)
4. Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49:694-699. (Pubitemid 351717532)
5. Tsuruda JS, Kortman KE, Bradley WG, et al. Radiation effects on cerebral white matter: MR evaluation. AJR Am J Roentgenol. 1987;149:165-171. (Pubitemid 17095022)
6. Mintz A, Perry J, Spithoff K, et al. Management of single brain metastasis: a practice guideline. Curr Oncol. 2007;14:131-143.
7. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
8. Sorensen AG, Batchelor TT, Wen PY, et al. Response criteria for glioma. Nat Clin Pract Oncol. 2008;5:634-644.
9. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol. 2008;29:419-424. (Pubitemid 351424049)
10. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000;217:377-384.
11. Finn MA, Blumenthal DT, Salzman KL, et al. Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol. 2007;67:246-250. (Pubitemid 46274888)
12. Henegar MM, Moran CJ, Silbergeld DL. Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg. 1996; 84:174-179. (Pubitemid 26039466)
13. Watling CJ, Lee DH, Macdonald DR, et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol. 1994;12:1886-1889. (Pubitemid 24349391)
14. Tsien C, Galbán CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in highgrade glioma. J Clin Oncol. 2010;28:2293-2299.
15. de Wit MC, de Bruin HG, Eijkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004; 63:535-537. (Pubitemid 39031388)
16. Brandsma D, Stalphers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9:453-461. (Pubitemid 351597795)
17. Barajas RF Jr, Chang JS, Segal MR, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility weighted contrast-enhanced perfusionMR imaging. Radiology. 2009;253:486-496.
18. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudoprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008;113:405-410.
19. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192-2197.
20. Gerstner ER, McNamara MB, Norden AD, et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudoprogression. J Neurooncol. 2009;94:97-101.
21. Cha S. Update on brain tumor imaging. AJNR Am J Neuroradiol. 2006;27: 475-487.
22. Belliveau JW, Rosen BR, Kantor HL, et al. Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med. 1990;14:538-546. (Pubitemid 20248637)
23. Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Reson Med. 1990;14:249-265. (Pubitemid 20248610)
24. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol. 2000;21:901-909. (Pubitemid 30262837)
25. Lupo JM, Cha S, Chang SM, et al. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol. 2005;26:1446-1454. (Pubitemid 43733445)
26. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25: 746-755. (Pubitemid 38657655)
27. Shin JH, Lee HK, Kwun BD, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. AJR Am J Roentgenol. 2002;179:783-789. (Pubitemid 34919600)
28. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. 2009;30:552-558.
29. Barajas RF, Chang JS, Sneed PK, et al. Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol. 2009;30:367-372.
30. HeestersMAAM, KammanR, Mooyaart EL, et al. Localized proton spectroscopy of in operable brain tumors. Response to radiation therapy. J Neurooncol. 1993;17:27-35. (Pubitemid 24006746)
31. McBride D, Miller BL, Nikas DL, et al. Analysis of brain tumors using 1H magneticresonance spectroscopy. Surg Neurol. 1995;44;137-144.
32. Usenius JP, Vaino P, Hernesniemi J, et al. Choline-containing compounds in human astrocytomas studied by 1H NMR spectroscopy in vivo and in vitro. J Neurochem. 1994;63:1538-1543. (Pubitemid 24299544)
33. Träber F, Block W, Flacke S, et al. MR spectroscopy of brain tumors in the course of radiation therapy: use of fast spectroscopic imaging and single-voxel spectroscopy for diagnosing recurrence [in German]. Rofo. 2002;174:33-42. (Pubitemid 34151442)
34. Ando K, Ishikura R, Nagami Y, et al. Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesions. Nippon Igaku Hoshasen Gakkai Zasshi. 2004;64:121-126.
35. Plotkin M, Eisenacher J, Bruhn H, et al. 123I-IMT SPECT and 1H MRspectroscopy at 3.0 T in the differential diagnois of recurrent or residual gliomas: a comparative study. J Neurooncol. 2004;70:49-58. (Pubitemid 39193997)
36. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther. 2003;2:497-507.
37. Rabinov JD, Lee PL, Barker FG, et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology. 2002;225:871-879. (Pubitemid 35387129)
38. Zeng QS, Li CF, Zhang K, et al. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent gliomas from radiation injury. J Neurooncol. 2007; 84:63-69. (Pubitemid 47103445)
39. Rock JP, Scarpace L, Hearshen D, et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery. 2002;51:912-920. (Pubitemid 36331026)
40. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol. 2001;22:604-612. (Pubitemid 32318684)
41. Patronas NJ, Di Chiro G, Brooks RA, et al. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology. 1982;144:885-889. (Pubitemid 12049740)
42. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48: 1468-1481. (Pubitemid 47397397)
43. Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?AJNR Am J Neuroradiol. 1998;19:407-413. (Pubitemid 30422740)
44. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322. (Pubitemid 28240345)
45. Nariai T, Tanaka Y, Wakimoto H, et al. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005;103 :498-507. (Pubitemid 43186642)
46. Miyagawa T, Oku T, Uehara H, et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab. 1998;18:500-509. (Pubitemid 28213534)
47. Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of 18FFDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39-51. (Pubitemid 40142777)
48. Tsuyuguchi N, Takami T, Sunada I, et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgeryVin malignant glioma. Ann Nucl Med. 2004; 18:291-296. (Pubitemid 39100096)
49. Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of O-(2-[18 F]fluoroethyl)-L-tyrosine (FET)-and L-[methyl-11C]methionine (MET)YPET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81:1049-1058.
50. Thiel A, Pietrzyk U, Sturm V, et al. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report. Neurosurgery. 2000;46:232-234. (Pubitemid 30030287)
51. Galldiks N, Ullrich R, Schroeter M, et al. Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastomamultiforme. Eur J Nucl Med Mol Imaging. 2010;37:84-92.
52. Tripathi M, Sharma R, Varshney R, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med. 2012;37:158-163.
53. Galldiks N, Kracht LW, Burghaus L, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging. 2006;33:516-524.
54. Galldiks N, Kracht LW, Burghaus L, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging. 2010;9:40-46.
55. Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol. 2009;95: 87-93.
56. Rachinger W, Goetz C, Pöpperl G, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57:505-511. (Pubitemid 41254459)
57. Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;46:904-911. (Pubitemid 46939941)
58. Xiangsong Z, Weian C. Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. J Neurooncol. 2007;82:305-311. (Pubitemid 46614394)
59. Tanaka Y, Nariai T, Momose T, et al. Glioma surgery using a multimodal navigation system with integrated metabolic images. J Neurosurg. 2009; 110:163-172